A Phase 3 Safety and Efficacy Study of Fovista® (E10030) Intravitreous Administration in Combination With Lucentis® Compared to Lucentis® Monotherapy

NCT01944839 · clinicaltrials.gov ↗

PHASE3

Phase

TERMINATED

Status

619

Enrollment

INDUSTRY

Sponsor class

Conditions

Age-Related Macular Degeneration

Interventions

DRUG: E10030
DRUG: ranibizumab
DRUG: E10030 sham intravitreal injection

Sponsor

Ophthotech Corporation